María San Anselmo, Elisabet Martí Coma-Cros, Teresa Sierra, Lívia Neves Borgheti-Cardoso, Xavier Fernàndez-Busquets, Juan José Valle-Delgado, Alexandre Lancelot, José Luis Serrano, Barcelona Institute of Science and Technology, University of Zaragoza, Department of Bioproducts and Biosystems, Aalto-yliopisto, Aalto University, Ministerio de Economía y Competitividad (España), Ministerio de Ciencia, Innovación y Universidades (España), Gobierno de Aragón, Generalitat de Catalunya, European Commission, Consejo Superior de Investigaciones Científicas (España), Lancelot, Alexandre, Neves Borgheti-Cardoso, Livia, Serrano, José Luis, Fernàndez-Busquets, Xavier, Sierra, Teresa, Lancelot, Alexandre [000-0002-9213-9186], Neves Borgheti-Cardoso, Livia [0000-0002-9655-8214], Serrano, José Luis [0000-0001-9866-6633], Fernàndez-Busquets, Xavier [0000-0002-4622-9631], and Sierra, Teresa [0000-0001-7091-077X]
Biomaterials for antimalarial drug transport still need to be investigated in order to attain nanocarriers that can tackle essential issues related to malaria treatment, e.g. complying with size requirements and targeting specificity for their entry into Plasmodium-infected red blood cells (pRBCs), and limiting premature drug elimination or drug resistance evolution. Two types of dendritic macromolecule that can form vehicles suitable for antimalarial drug transport are herein explored. A new hybrid dendritic-linear-dendritic block copolymer based on Pluronic® F127 and amino terminated 2,2′-bis(glycyloxymethyl)propionic acid dendrons with a poly(ester amide) skeleton (HDLDBC-bGMPA) and an amino terminated dendronized hyperbranched polymer with a polyester skeleton derived from 2,2′-bis(hydroxymethyl)propionic acid (DHP-bMPA) have provided self-assembled and unimolecular micelles. Both types of micelle carrier are biocompatible and exhibit appropriate sizes to enter into pRBCs. Targeting studies have revealed different behaviors for each nanocarrier that may open new perspectives for antimalarial therapeutic approaches. Whereas DHP-bMPA exhibits a clear targeting specificity for pRBCs, HDLDBC-bGMPA is incorporated by all erythrocytes. It has also been observed that DHP-bMPA and HDLDBC-bGMPA incorporate into human umbilical vein endothelial cells with different subcellular localization, i.e. cytosolic and nuclear, respectively. Drug loading capacity and encapsulation efficiencies for the antimalarial compounds chloroquine, primaquine and quinacrine ranging from 30% to 60% have been determined for both carriers. The resulting drug-loaded nanocarriers have been tested for their capacity to inhibit Plasmodium growth in in vitro and in vivo assays., This research was supported by grants BIO2014-52872-R, CTQ2015-70174-P, MAT2015-66208-C3-1-P (Ministerio de Ciencia, Innovación y Universidades, Spain, including FEDER funds), 2014-SGR-938 (Generalitat de Catalunya, Spain), and (Gobierno de Aragón-FSE). ISGlobal and IBEC are members of the CERCA Programme, Generalitat de Catalunya. A. L. thanks the Ministerio de Ciencia, Innovación y Universidades for his grant (FPU12/05210). L. N. B.-C. is supported by the European Commission under Horizon 2020's Marie Skłodowska-Curie Actions COFUND scheme (Grant Agreement no. 712754) and by the MINECO's Severo Ochoa programme (Grant SEV-2014-0425 (2015–2019))., The authors acknowledge support of the publication fee by the CSIC Open Access Publication Support Initiative through its Unit of Information Resources for Research (URICI).